Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth ...

When investors choose to risk their capital in an individual company, they must be aware that the stock market isn’t the ...

Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

Investing.com -- Analysts at Citi and Bank of America are maintaining a cautious stance on Hims & Hers Health as competition in the GLP-1 space intensifies and growth begins to moderate.

Hims & Hers (NYSE: HIMS) has put investors on a roller coaster ride in 2025. *Stock prices used were the afternoon prices of ...

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of ...

A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury ...

Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% YoY. Check out why I ...